For the year ending 2025-12-31, PLRX had -$25,743K decrease in cash & cash equivalents over the period. -$128,710K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -149,344 |
| Depreciation expense | 1,696 |
| Stock-based compensation expense | 26,234 |
| Gain on sale of property plant and equipment | 44 |
| Non-cash operating lease expense | 3,277 |
| Amortization (accretion) on short-term investments | -3,956 |
| Loss on extinguishment of debt | -1,828 |
| Prepaid expenses and other current assets | -2,541 |
| Other non-current assets | -43 |
| Accounts payable | -5,480 |
| Accrued liabilities | -12,167 |
| Operating lease liabilities | -876 |
| Net cash used in operating activities | -128,336 |
| Purchase of short-term investments | 203,404 |
| Maturity of short-term investments | 337,913 |
| Purchase of property and equipment | 374 |
| Proceeds from sale of property, plant and equipment | 155 |
| Net cash provided by investing activities | 134,290 |
| Proceeds from issuances of common stock under benefit plans | 570 |
| Payment of debt | 32,267 |
| Proceeds from term loan, net of issuance costs | 0 |
| Net cash (used in) provided by financing activities | -31,697 |
| Net (decrease) increase in cash and cash equivalents | -25,743 |
| Cash, cash equivalents and restricted cash at end of period | 72,670 |
| Cash, cash equivalents and restricted cash at beginning of period | 46,927 |
PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)